US 12,215,112 B2
CD151 inhibitors
John Thomas Feutrill, Rosanna (AU); Jean-Marc Garnier, Ocean Grove (AU); and Albert George Frauman, Melbourne (AU)
Assigned to ESFAM BIOTECH PTY LTD, Melbourne (AU)
Appl. No. 18/006,978
Filed by ESFAM BIOTECH PTY LTD, Melbourne (AU)
PCT Filed Jul. 27, 2021, PCT No. PCT/AU2021/050816
§ 371(c)(1), (2) Date Jan. 26, 2023,
PCT Pub. No. WO2022/020888, PCT Pub. Date Feb. 3, 2022.
Claims priority of application No. 2020902630 (AU), filed on Jul. 27, 2020.
Prior Publication US 2023/0365567 A1, Nov. 16, 2023
Int. Cl. C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 19 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
Formula (I)
wherein
R1, R2, and R3 are each independently selected from the group consisting of H and C1-C12alkyl,
R4 is selected from the group consisting of H and C1-C12alkyl,
R5 is selected from the group consisting of H, optionally substituted C6-C18aryl, optionally substituted C1-C18heteroaryl, optionally substituted C6-C18arylC1-C12alkyl-, and optionally substituted C1-C18heteroarylC1-C12alkyl-;
R6 is selected from the group consisting of H, C1-C12alkyl, C3-C6 cycloalkyl, and C1-C5 heterocycloalkyl,
R7 is selected from the group consisting of H and C1-C12alkyl;
R8 is selected from the group consisting of H, C1-C12alkyl, optionally substituted C6-C18aryl, optionally substituted C1-C18heteroaryl, optionally substituted C6-C18arylC1-C12alkyl-, and optionally substituted C1-C18heteroarylC1-C12alkyl-;
or R7 and R8 when taken together with the nitrogen atom to which they are attached form an optionally substituted C2-C12heterocyclic group;
or a pharmaceutically acceptable salt thereof.